Warren Blames GSK for Flovent Shortage, Leaving Kids Without Vital Asthma Drug
• Warren accused GSK of “price gouging” by stopping production of the common children’s asthma drug Flovent to avoid rebate regulations, putting millions at risk.
• Flovent is no longer available, leaving families scrambling to find alternatives ahead of allergy season.
• The generic version is technically cheaper but lacks the rebates of the brand name, so some insurers won't cover it.
• Doctors worry there may be an uptick in ER visits and that lower income families will suffer most from losing access.
• One mother struggled to find an alternative for her son, who went without medication for 9 days and still lacks proper dosage of new drug.